Pharmaceutical patents need a new lease of life
Patrick Duxbury and Emma Tuck ask whether the increasing cost of drug development, and the declining numbers of drugs being approved, mean that IP protection for life science products should be reevaluated
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), by 2006 the cost of researching and developing a new chemical or biological product had reached on average 1,059 million ($1,318 million). Increasing regulation, price control, competition and challenges...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.